Clinical trials: Premenopausal
Menopause, Cardiac Function Impaired
Effects of Exercise Training on Cardiovascular Health in Middle-aged Women
The hypothesis of the present study is that physical training can oppose detrimental changes in cardiovascular and metabolic health associated with estrogen loss after menopause.
- Conditions
- Menopause, Cardiac Function Impaired, Cardiovascular Diseases, Blood Platelet Disorders
- Trial name
- NCT02135575
- Testing
- Spinning
- Where
- Denmark
- Volunteers
- 36 people, healthy volunteers welcome
- Sponsor
- University of Copenhagen
Cardiometabolic Health in Premenopausal and Postmenopausal Women
Intermittent Walking Training and Cardiometabolic Health in Premenopausal and Postmenopausal Women
The goal of this clinical trial is to compare premenopausal and postmenopausal women regarding the effects of a 10-week moderate-intensity intermittent walking training (MIWT) program on aerobic capacity and selected…
- Trial name
- NCT07555457
- Testing
- Moderate-Intensity Intermittent Walking Training (MIWT)
- Where
- Tunisia
- Volunteers
- 32 people
- Sponsor
- High Institute of Sports and Physical Education of Kef
Breast Cancer
Genetic Study of CYP2D6 Enzyme and Therapeutic Drug Monitoring of Tamoxifen
Aim of work: 1. To estimate the frequency of Cyp2D6*1 and *4 alleles in Egyptian patients maintained on tamoxifen (20 mg/day) for management of ER +ve breast cancer. 2.
- Trial name
- NCT03582865
- Testing
- Tamoxifen 20 mg
- Volunteers
- 100 people
- Sponsor
- Assiut University
Breast Cancer
Fulvestrant in Premenopausal Women With Hormone Receptor-Positive Breast Cancer
The purpose of this study is to test the effectiveness and safety of fulvestrant in premenopausal women with advanced breast cancer.
- Trial name
- NCT00146601
- Testing
- Fulvestrant
- Where
- 4 sites in United States
- Volunteers
- 35 people
- Sponsor
- Dana-Farber Cancer Institute
Breast Cancer
Tamoxifen Versus Anastrozole, Alone or in Combination With Zoledronic Acid
The primary objective is, first, the comparison of tamoxifen and anastrozole and, second, the comparison of zoledronate added to standard adjuvant therapy with controls according to disease-free survival (DFS) in premenopausal…
- Trial name
- NCT00295646
- Testing
- tamoxifen, anastrozole, zoledronic acid
- Where
- 72 sites in Austria, Germany
- Volunteers
- 1,803 people
- Sponsor
- Austrian Breast & Colorectal Cancer Study Group
The Neoadjuvant Therapy
The Neoadjuvant Combined Hormone Therapy in Premenopausal Women With Locally Advanced ER+/HER2- Breast Cancer
Breast cancer take a leading position in the structure of morbidity and mortality from malignant tumors among women. Today the interest of many scientists and pharmaceutical companies is focused on the study of metastatic breast…
- Trial name
- NCT04753177
- Testing
- Ribocyclib, fulvestrant, triptorelin, Doxorubicin, cyclophosphamide, paclitaxel
- Where
- Russia
- Volunteers
- 120 people
- Sponsor
- Saint Petersburg State Budgetary Healthcare Institution, City Clinical Oncology Dispensary
Overweight
Orlistat Induced Modulation on the Fatty Acid Composition in Obese Females
Orlistat is a popular drug approved for long-term use which produces weight loss by inhibiting triglycerides, main components of fats in the diet and reducing dietary fat absorption by up to 30%.
- Trial name
- NCT01414465
- Testing
- Orlistat
- Where
- Brazil
- Volunteers
- 17 people, healthy volunteers welcome
- Sponsor
- University of Campinas, Brazil
Menstrual Wellness
Radicle Menstrual Wellness™ CSP: A Trial Evaluating Plant-Based Health and Wellness Products on Menstrual Wellness in Premenopausal Women
A randomized, double-blind, placebo-controlled, trial evaluating plant-based health and wellness products on menstrual wellness in premenopausal women
- Trial name
- NCT07138339
- Testing
- Menstrual Wellness Product 1
- Where
- United States
- Volunteers
- 850 people, healthy volunteers welcome
- Sponsor
- Radicle Science
Type 1 Diabetes Mellitus
Development of an Advisory System for Glycemic Control During the Menstrual Cycle in Patient With Type 1 Diabetes
This overall research goal will be to develop a mobile-based module to improve glycemic control during the menstrual cycle in women with Type 1 diabetes mellitus (T1DM).
- Trial name
- NCT01653210
- Where
- United States
- Volunteers
- 15 people
- Sponsor
- University of Virginia
Breast Cancer, Osteoporosis
Tamoxifen to Prevent Bone Loss and Heart Disease in Premenopausal Women Receiving Chemotherapy for Stage I or Stage II Breast Cancer
RATIONALE: Tamoxifen may be able to increase bone density and decrease cholesterol in women who are undergoing chemotherapy for breast cancer.
- Trial name
- NCT00005605
- Where
- United States
- Volunteers
- 79 people
- Sponsor
- Northwestern University
Breast Cancer
High-Dose Combination Chemotherapy Plus Peripheral Stem Cell Transplantation Compared With Standard Combination Chemotherapy in Treating Women With High-Risk Breast Cancer
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Combining chemotherapy with peripheral stem cell transplantation may allow the doctor to give higher doses of…
- Trial name
- 15-95 (NCT00002784)
- Testing
- filgrastim, CMF regimen, cyclophosphamide
- Where
- 11 sites in Australia, Switzerland
- Volunteers
- 344 people
- Sponsor
- ETOP IBCSG Partners Foundation
Healthy
Effect of BI 207127 + Faldaprevir on Blood Levels of Oral Contraceptives Containing Ethinylestradiol and Levonorgestrel
Investigate the effect of multiple oral doses of BI 207127 + faldaprevir (FDV) on the multiple dose pharmacokinetics of ethinylestradiol and levonorgestrel (Microgynon®) in healthy premenopausal female volunteers.
- Trial name
- NCT01941615
- Testing
- faldaprevir, Microgynon®, BI 207127
- Where
- Germany
- Volunteers
- 18 people, healthy volunteers welcome
- Sponsor
- Boehringer Ingelheim
Early Breast Cancer
Pregnancy Outcome and Safety of Interrupting Therapy for Women With Endocrine Responsive Breast Cancer
The best available evidence suggests that pregnancy after breast cancer does not increase a woman's risk of developing a recurrence from her breast cancer.
- Trial name
- POSITIVE (NCT02308085)
- Testing
- Endocrine therapy interruption
- Where
- 211 sites in United States, Australia and 20 more
- Volunteers
- 518 people
- Sponsor
- ETOP IBCSG Partners Foundation
Estrogen Receptor Positive Breast Cancer, Progesterone Receptor Positive Tumor
Suppression of Ovarian Function With Either Tamoxifen or Exemestane Compared With Tamoxifen Alone in Treating Premenopausal Women With Hormone-Responsive Breast Cancer
RATIONALE: Estrogen can stimulate the growth of breast tumor cells. Ovarian function suppression combined with hormone therapy using tamoxifen or exemestane may fight breast cancer by reducing the production of estrogen.
- Conditions
- Estrogen Receptor Positive Breast Cancer, Progesterone Receptor Positive Tumor, Recurrent Breast Carcinoma, Stage IA Breast Cancer
- Trial name
- SOFT (NCT00066690)
- Testing
- Exemestane, Laboratory Biomarker Analysis, Oophorectomy
- Where
- 500 sites in United States, Canada and 1 more
- Volunteers
- 3,066 people
- Sponsor
- ETOP IBCSG Partners Foundation
Uterine Fibroids, Heavy Menstrual Bleeding
Efficacy and Safety of BG2109 in Subjects With Heavy Menstrual Bleeding Associated With Uterine Fibroids.
The primary objective of this study is to demonstrate the superior efficacy versus placebo of BG2109 alone and in combination with add-back therapy for the reduction of heavy menstrual bleeding associated with uterine fibroids in…
- Trial name
- NCT05620355
- Testing
- BG2109, Add-back therapy
- Where
- 29 sites in China
- Volunteers
- 312 people
- Sponsor
- Bio Genuine (Shanghai) Biotech Co., Ltd.
Vitamin D Deficiency, Calcium
Resistive Exercise Versus HIIT on Calcium and Vitamin D
A comparison between resistive exercise and high intensity interval trainig on calcium and vitamin d in premenopausal women.
- Conditions
- Vitamin D Deficiency, Calcium, Premenopause
- Trial name
- NCT05795504
- Testing
- resistive exercise, high intensity interval training, calcium and vitamin D
- Where
- Egypt
- Volunteers
- 60 people, healthy volunteers welcome
- Sponsor
- Cairo University
Osteoporosis, Osteopenia
Effects of Jumping on Bone Health in Young Women
This study evaluates the longitudinal, dose-dependent effects of jumping on bone health in young women. The women will be divided into 9 groups of varying jump height and repetitions, with a tenth group serving as control.
- Trial name
- NCT03413540
- Testing
- Jump
- Volunteers
- 357 people, healthy volunteers welcome
- Sponsor
- California State University, San Marcos
Breast Cancer
Study on Pre-menopausal Patients With Advanced ER and PR + BC Treated With Arimidex Plus Zoladex
The purpose of this study is to determine the efficacy and tolerance of the association of two drugs already marketed and used to treat your disease: Arimidex® 1 Mg per day per os and Zoladex® 3,6 Mg in injections under cutaneous…
- Trial name
- NCT00235937
- Testing
- Anastrozole and goserelin
- Where
- 7 sites in France
- Volunteers
- 45 people
- Sponsor
- AstraZeneca
the Efficacy of Aromatase Inhibitor vs. Gonadotrpins Releasing Hormone Agonists in Treating Premenopausal Women With Uterine Adenomyosis
Aromatase Inhibitors or GnRH-a for Uterine Adenomyosis
To date, there is no uniform agreement on the most appropriate therapeutic methods for managing women with uterine adenomyosis and/or adenomyoma who want to preserve their fertility.
- Trial name
- NCT01218581
- Testing
- received oral letrozole (2.5 mg/day)and goserelin subcutaneosly (3.6 mg/month)
- Where
- Egypt
- Volunteers
- 32 people
- Sponsor
- Mansoura University
Pre-menopausal Breast Cancer, PI3K Pathway Inhibition
A Phase Ib Dose De-escalation Study With BYL719 in Premenopausal Patients With Locally Advanced or Metastatic Breast Cancer
Based on the evidence acquired in the post-menopausal setting with everolimus and on pre-clinical evidences supporting the investigation of PI3K inhibitors, such as alpelisib and buparlisib, in combination with endocrine therapy…
- Trial name
- B-YOND (NCT02058381)
- Testing
- alpelisib (BYL719), buparlisib (BKM120)
- Where
- 15 sites in Hong Kong, South Korea and 2 more
- Volunteers
- 40 people
- Sponsor
- Novartis Pharmaceuticals